title: New biologic agents for the treatment of cutaneous T-cell lymphoma.
abstract: Cutaneous T-cell lymphoma (CTCL) is typically a skin-infiltrating malignancy of clonally derived CD4+ T lymphocytes. Because the host antitumor response appears to play an important role in disease control, systemic therapeutic agents are used in such a manner as to preserve the integrity of the host antitumor response while selectively targeting the malignant cells. The new biologic response-modifying treatment options currently used to treat CTCL are reviewed.
authors.affiliation: University of Pennsylvania, School of Medicine, Philadelphia, PA 19104, USA.
authors.forename: Carmela C
authors.initials: CC
authors.lastname: Vittorio
authors.forename: Jacqueline M
authors.initials: JM
authors.lastname: Junkins-Hopkins
authors.forename: Karen S
authors.initials: KS
authors.lastname: McGinnis
authors.forename: Michael
authors.initials: M
authors.lastname: Shapiro
authors.forename: Maria
authors.initials: M
authors.lastname: Wysocka
authors.forename: Mohamed H
authors.initials: MH
authors.lastname: Zaki
authors.forename: Lars E
authors.initials: LE
authors.lastname: French
authors.forename: Alain H
authors.initials: AH
authors.lastname: Rook
mesh_terms: D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D016399:Lymphoma, T-Cell / Q000188:drug therapy* / Q000276:immunology; D017893:Photopheresis; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000276:immunology
chemical_list: D007155:Immunologic Factors